TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
Cytiva BioProcess R&D AB
Closing information (x1000 DKK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
8,497,952
|
8,589,112
|
11,367,800 |
| Financial expenses |
2,493
|
0
|
7,713 |
| Earnings before taxes |
2,642,251
|
4,044,656
|
6,616,809 |
| EBITDA |
8,125,853
|
8,237,570
|
11,016,209 |
| Total assets |
16,152,938
|
24,815,882
|
23,662,667 |
| Current assets |
6,079,109
|
10,031,697
|
8,801,979 |
| Current liabilities |
8,072,179
|
9,564,698
|
15,288,255 |
| Equity capital |
8,080,759
|
15,251,184
|
7,707,407 |
| - share capital |
65
|
67
|
67 |
| Employees (average) |
0
|
0
|
0 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
50.0%
|
61.5%
|
32.6% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
31.1%
|
47.1%
|
58.2% |
| Return on assets (ROA) |
16.4%
|
16.3%
|
28.0% |
| Current ratio |
75.3%
|
104.9%
|
57.6% |
| Return on equity (ROE) |
32.7%
|
26.5%
|
85.9% |
| Change turnover |
192,935
|
-2,837,229
|
1,487,111 |
| Change turnover % |
2%
|
-25%
|
15% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.